aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma (Nasdaq: ATYR) has announced the approval of inducement grants for three new employees by its Board's Compensation Committee on March 21, 2025. The grants consist of nonstatutory stock options to purchase 43,800 shares at a weighted-average price of $3.69 per share, matching the weighted-average closing price on Nasdaq Capital Market.
The stock options, granted under the aTyr Pharma 2022 Inducement Plan, feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4).
aTyr is developing first-in-class medicines from its tRNA synthetase platform, with its lead candidate efzofitimod targeting interstitial lung disease treatment.
aTyr Pharma (Nasdaq: ATYR) ha annunciato l'approvazione di concessioni di incentivo per tre nuovi dipendenti da parte del Comitato per la Compensazione del Consiglio il 21 marzo 2025. Le concessioni consistono in opzioni su azioni non statutarie per l'acquisto di 43.800 azioni a un prezzo medio ponderato di $3.69 per azione, corrispondente al prezzo medio ponderato di chiusura sul Nasdaq Capital Market.
Le opzioni su azioni, concesse nell'ambito del Piano di Incentivo aTyr Pharma 2022, prevedono un programma di maturazione di quattro anni con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nel corso di tre anni, a condizione di continuare l'impiego. Queste concessioni sono conformi alla Regola di quotazione Nasdaq 5635(c)(4).
aTyr sta sviluppando medicinali di prima classe dalla sua piattaforma di sintasi tRNA, con il suo candidato principale efzofitimod che mira al trattamento della malattia polmonare interstiziale.
aTyr Pharma (Nasdaq: ATYR) ha anunciado la aprobación de concesiones de incentivo para tres nuevos empleados por parte del Comité de Compensación de su Junta el 21 de marzo de 2025. Las concesiones consisten en opciones sobre acciones no estatutarias para la compra de 43,800 acciones a un precio promedio ponderado de $3.69 por acción, coincidiendo con el precio promedio ponderado de cierre en el Nasdaq Capital Market.
Las opciones sobre acciones, otorgadas bajo el Plan de Incentivo aTyr Pharma 2022, cuentan con un calendario de adquisición de cuatro años, con un 25% de adquisición después de un año y el 75% restante adquiriéndose mensualmente durante tres años, condicionado a la continuidad del empleo. Estas concesiones cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
aTyr está desarrollando medicamentos de primera clase a partir de su plataforma de sintasa de tRNA, siendo su candidato principal efzofitimod, que se dirige al tratamiento de la enfermedad pulmonar intersticial.
aTyr Pharma (Nasdaq: ATYR)는 2025년 3월 21일 이사회 보상위원회에서 세 명의 신입 직원에 대한 유인 보상 승인을 발표했습니다. 이 보상은 $3.69의 가중 평균 가격으로 43,800주를 구매할 수 있는 비상장 주식 옵션으로 구성되어 있으며, 이는 Nasdaq 자본 시장의 가중 평균 종가와 일치합니다.
이 주식 옵션은 aTyr Pharma 2022 유인 계획에 따라 부여되며, 4년의 분할 일정으로 구성되어 있습니다. 1년 후 25%가 분할되고 나머지 75%는 3년에 걸쳐 매월 분할됩니다. 이는 계속 고용되는 조건입니다. 이 보상은 Nasdaq 상장 규정 5635(c)(4)에 부합합니다.
aTyr는 tRNA 합성효소 플랫폼에서 1급 의약품을 개발하고 있으며, 주요 후보인 efzofitimod는 간질성 폐질환 치료를 목표로 하고 있습니다.
aTyr Pharma (Nasdaq: ATYR) a annoncé le 21 mars 2025 l'approbation de subventions d'incitation pour trois nouveaux employés par le Comité de Rémunération de son Conseil. Les subventions consistent en des options d'achat d'actions non statutaires pour l'achat de 43 800 actions à un prix moyen pondéré de $3.69 par action, correspondant au prix moyen pondéré de clôture sur le Nasdaq Capital Market.
Les options d'achat d'actions, accordées dans le cadre du Plan d'Incitation aTyr Pharma 2022, comportent un calendrier d'acquisition de quatre ans avec 25 % d'acquisition après un an et les 75 % restants acquérant mensuellement sur trois ans, sous réserve de la poursuite de l'emploi. Ces subventions sont conformes à la Règle de Cotation Nasdaq 5635(c)(4).
aTyr développe des médicaments de première classe à partir de sa plateforme de synthétase tRNA, avec son candidat principal efzofitimod ciblant le traitement de la maladie pulmonaire interstitielle.
aTyr Pharma (Nasdaq: ATYR) hat am 21. März 2025 die Genehmigung von Anreizvergaben für drei neue Mitarbeiter durch den Vergütungsausschuss des Vorstands bekannt gegeben. Die Vergaben bestehen aus nicht-statutären Aktienoptionen zum Kauf von 43.800 Aktien zu einem gewichteten Durchschnittspreis von $3.69 pro Aktie, was dem gewichteten Durchschnittsschlusskurs am Nasdaq Capital Market entspricht.
Die Aktienoptionen, die im Rahmen des aTyr Pharma 2022 Incentive-Plans gewährt werden, haben einen vierjährigen Vesting-Zeitplan, bei dem 25% nach einem Jahr und die verbleibenden 75% monatlich über drei Jahre vesten, abhängig von der Fortsetzung des Arbeitsverhältnisses. Diese Vergaben entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
aTyr entwickelt erstklassige Medikamente aus seiner tRNA-Synthetase-Plattform, wobei der Hauptkandidat efzofitimod auf die Behandlung von interstitieller Lungenerkrankung abzielt.
- Company maintains ability to attract talent through equity compensation
- Structured vesting schedule helps retain employees over 4-year period
- Potential shareholder dilution from 43,800 new shares
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors approved on March 21, 2025 an aggregate of three grants to three employees of nonstatutory stock options to purchase an aggregate of 43,800 shares of aTyr’s common stock with a weighted-average exercise price of
Each option vests over a period of four years, with
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
What are the terms of aTyr Pharma's (ATYR) March 2025 inducement grants?
How many employees received stock options in aTyr Pharma's March 2025 inducement grants?
What is the vesting schedule for aTyr Pharma's (ATYR) March 2025 inducement grants?
What is aTyr Pharma's (ATYR) lead therapeutic candidate?
